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Summary
Measurement of BCR activator of RhoGEF and GTPase -ABL proto-
oncogene 1, non-receptor tyrosine kinase (BCR-ABL1) mRNA levels by
reverse transcription quantitative polymerase chain reaction (RTqPCR) has
been critical to treatment protocols and clinical trials in chronic myeloid
leukaemia; however, interlaboratory variation remains a significant issue.
Reverse transcriptase droplet digital PCR (RTddPCR) has shown potential
to improve testing but a large-scale interlaboratory study is required to
definitively establish this. In the present study, 10 BCR-ABL1-positive sam-
ples with levels ranging from molecular response (MR)10–MR50 were
tested by 23 laboratories using RTddPCR with the QXDX BCR-ABL %IS
kit. A subset of participants tested the samples using RTqPCR. All 23 par-
ticipants using RTddPCR detected BCR-ABL1 in all samples to MR40.
Detection rates for deep-response samples were 957% at MR45, 783% at
MR47 and 870% at MR50. Interlaboratory coefficient of variation was
indirectly proportional to BCR-ABL1 level ranging from 293% to 690%.
Linearity ranged from 09330 to 1000 (average 09936). When results were
compared for the 11 participants who performed both RTddPCR and
RTqPCR, RTddPCR showed a similar limit of detection to RTqPCR with
reduced interlaboratory variation and better assay linearity. The ability to
detect deep responses with RTddPCR, matched with an improved linearity
and reduced interlaboratory variation will allow improved patient manage-
ment, and is of particular importance for future clinical trials focussed on
achieving and maintaining treatment-free remission.
Keywords: BCR-ABL1, external quality assessment (EQA), Quality, CML,
RTddPCR.
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Introduction
Sequential measurement of BCR activator of RhoGEF and
GTPase-ABL proto-oncogene 1, non-receptor tyrosine kinase
(BCR-ABL1) mRNA levels by reverse transcription quantita-
tive polymerase chain reaction (RTqPCR) is now embedded
in standard patient management protocols for chronic mye-
loid leukaemia (CML)1 and is a validated surrogate outcome
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for traditional clinical outcomes in trials of new therapies for
patients with CML.2 It has played a seminal role in the
remarkable improvement in patient survival seen in this dis-
ease, where the majority of patients with chronic phase dis-
ease now have a normal life expectancy.3
This improvement in life expectancy has led to a change
in emphasis for the clinicians and researchers treating CML,
from extending patient survival to curing the disease. Cur-
rent aims for treatment in CML are to achieve a faster
molecular response (MR), preventing progression to blastic
phase disease allowing a stable deep MR and tyrosine kinase
inhibitor (TKI) treatment discontinuation for treatment-free
remission (TFR).4,5 With RTqPCR being used to monitor the
speed of response, and define eligibility for TFR ever more
accurate and precise measurement of BCR-ABL1 is desirable,
to ensure that these important treatment decisions are made
on the best data available with optimal comparability
between laboratories. Efforts to standardise the current ‘gold
standard’ approach for BCR-ABL1 measurement, RTqPCR,6,7
including the development of the International Scale (IS),8–10
has reduced inter- and intralaboratory variation in BCR-
ABL1 measurement;11 however, the inherent complexity of
RTqPCR means that inter- and intralaboratory variation
remains a significant issue for laboratories,8,11 that still needs
to be addressed.
It has been speculated that reverse transcriptase droplet
digital PCR (RTddPCR) may overcome some of the variabil-
ity inherent to RTqPCR, particularly when measuring very
low BCR-ABL1 transcript levels. RTddPCR separates a bulk
PCR reaction into thousands of droplet-based single mole-
cule reactions, allowing a more accurate quantification of the
number of target molecules. In contrast to RTqPCR,
RTddPCR does not rely on the indirect relationship between
the amplification of the BCR-ABL1 transcript in patient sam-
ples and a calibration curve to quantify BCR-ABL1 levels, a
complex approach that is vulnerable to potential error.
Instead, it is a direct measurement of the number of copies
of the target molecule. Encouragingly, initial studies have
displayed a lower limit of detection (LOD) and limit of
quantification compared to RTqPCR.12–15 The Life After
Stopping TKIs (LAST) study showed that the superior LOD
of RTddPCR over RTqPCR may allow for less frequent mon-
itoring, resulting in less hospital visits for patients.16 Large-
scale, multicentre studies are required to assess if the benefits
of RTddPCR shown in single-centre studies can be replicated
in a multicentre study.
Methods
A total of 10 cell-line based BCR-ABL1 positive samples (la-
belled A–J in a random order) with BCR-ABL1 levels ranging
from MR10 (10% BCR-ABLIS)–MR50 (0001% BCR-ABL1IS)
were manufactured from a mixture of BCR-ABL1 (e14a2)-
positive K562 cells in a background of BCR-ABL1-negative
HL60 cells. K562 and HL60 cell lines were obtained from the
Deutsche Sammlung von Mikroorganismen und Zellkulturen
GmbH (DSMZ, Braunschweig, Germany). The HL60 and
K562 cultures tested negative for human immunodeficiency
virus (HIV), hepatitis B virus (HBV), hepatitis C virus
(HCV), cytomegalovirus (CMV), Epstein–Barr virus (EBV),
human T-lymphotrophic virus type I and II (HTLV-I/II),
human herpes virus 8 (HHV-8) and mycoplasma by PCR.
Cell lines were grown in RPMI 1640 (Thermo Fisher, Wal-
tham, USA) medium supplemented with 10% fetal bovine
serum (Thermo Fisher). Pre-defined dilutions of K562 cells
in HL60 cells were then prepared and freeze dried in 3-ml
glass ampoules to contain 9 9 106 cells. Samples were dried
for 24 h. Prior to distribution, to establish that the manufac-
tured samples accurately represented the target values, and to
ensure sample quality and homogeneity, a minimum of three
selected samples were subjected to (phenol chloroform) RNA
extraction, complementary DNA (cDNA) synthesis and BCR-
ABL1 quantification. This was performed using the Qiagen
Ipsogen BCR-ABL1 Mbcr kit (Qiagen, Hilden, Germany) and
the Applied Biosystems 7500 RQ-PCR machine (Thermo
Fisher) and the QXDX BCR-ABL %IS kit (Bio-Rad, Her-
cules, CA, USA) and QX200 Auto DG system (Bio-Rad).
Data analysis was performed in line with UK recommenda-
tions.17 Sample quality was defined as RNA OD260/280 ratio
of between 18 and 22 and ABL1 levels >100 000/replicate.
The percentage BCR-ABL1IS results from pre issue testing
were required to be within 12-fold of the target value, as
this is approaching the degree of reproducibility seen within
laboratories8,18 (Table SI). Stability of trial samples was
ensured by measuring ABL1 levels on a further three vials at
trial closure. Samples A–G were formulated to contain BCR-
ABL1 levels between MR10 (10% BCR-ABLIS)- and MR40
(001% BCR-ABLIS)- at half log intervals, important to detect
within standard treatment protocols. Samples H–J repre-
sented ‘deep-response’ levels [MR45 (00033% BCR-ABLIS)-,
MR47 (0002% BCR-ABLIS)- and MR50 (0001% BCR-
ABLIS)-], important to detect in treatment discontinuation
protocols.
The samples were shipped at ambient temperature to 26
study participants in 15 countries in Europe, Asia and North
America. All participants in the study were asked to extract
RNA and perform reverse transcription using their standard
in-house protocol and test the samples with the QXDX BCR-
ABL %IS kit, using either the QX200 auto or manual DG
system. Results from the QXDX BCR-ABL %IS kit are
reported on the IS by using an assay specific conversion fac-
tor determined by comparing the assay to an IS reference
value. Samples A–G used two reaction wells. Samples H–J
used four reaction wells. Participants were asked to indepen-
dently analyse RTddPCR data using the QuantaSoft (version
1.7.4) and QXDx Reporter Tool software. Where participants
were currently reporting BCR-ABL1 quantification results
using RTqPCR, all study samples were run using local
methodology for processing and analysis for comparison to
the RTddPCR results (n = 11).
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Final BCR-ABLIS levels for each sample were then calculated
and reported independently by each participant (along with
methodological information) using a dedicated online data
entry page. Method averages were calculated using an arith-
metic mean and significance calculated using a two-tailed t-
test. A P < 005 was defined as statistically significant.
Methodological variance was calculated using coefficient
of variation (CV) with an F-test for two-sample variance
used to calculate significance in Microsoft Excel. A P < 005
was defined as statistically significant. Assay linearity was cal-
culated using a simple linear regression (R2) in GraphPad
Prism (version 83.1). R2 > 099 was deemed satisfactory. A
Fisher r-to-z transformation was used to create a z value that
was used to assess the significance of difference between the
two correlation coefficients. A P < 005 was defined as statis-
tically significant.
Results
Results were returned by 23/26 (880%) participants. All
returned RTddPCR data (Table I; Fig 1) with 11 participants
returning both RTqPCR and RTddPCR data (Table II;
Fig 2).
All 23 participants using RTddPCR detected BCR-ABL1 in
all samples down to MR40. Detection rates for the deep-
response samples were 957% at MR45 (00033% BCR-
ABLIS)-, 783% at MR47 (0002% BCR-ABLIS)- and 870% at
MR50 (0001% BCR-ABLIS)- (Table SII). Interlaboratory CV
ranged from 293% at MR25 (033% BCR-ABLIS)- to 529%
at MR40 (001% BCR-ABLIS)- (Table I). For deep-response
samples, the CV was 597% at MR45 (00033% BCR-ABLIS)-,
616% at MR47 (0002% BCR-ABLIS)- and 690% at MR50
(0001% BCR-ABLIS)- (Table I). Linearity (R2) was assessed
for all participants using RTddPCR results from MR10 (10%
BCR-ABLIS)- to MR40 (001% BCR-ABLIS)- and ranged
between 09330 and 1000 (average 09936) (Fig 3;
Table SIII). Overall, 20/23 laboratories had a satisfactory
assay linearity with R2 > 099.
In total, 11 participants performed both RTddPCR and
RTqPCR. When the average percentage BCR-ABLIS results
reported by participants using RTqPCR was compared to the
average percentage BCR-ABLIS result for participants using
RTddPCR, the results were seen to be comparable, with no
statistically significant difference demonstrated (Table II).
There was no statistically significant difference seen in the
median ABL1 control gene levels calculated from partici-
pant’s RTddPCR data compared to RTqPCR (Table SIV;
Table SV).
When detections rates were compared for participants
who performed both RTddPCR and RTqPCR, all participants
detected BCR-ABL1 in all samples down to MR40 (001%
BCR-ABLIS)-, using both techniques. For deep-response sam-
ples, RTddPCR showed a detection rate of 909% at MR45
(001% BCR-ABLIS)-, 818% at MR47 (0033% BCR-ABLIS)-
and 818% at MR50 (0001% BCR-ABLIS)- compared to
909% at MR45 (0033% BCR-ABLIS)-, 909% at MR47
(002% BCR-ABLIS)- and 727% at MR50 (0001% BCR-
ABLIS)- for RTqPCR (Table SVI).
Interlaboratory CV was lower across all 10 samples for
RTddPCR when compared to RTqPCR (Table II, Fig 2) with
RTddPCR CV ranging from 185% for sample D [MR25
(033% BCR-ABLIS)-] to 441% for sample A [MR40 (001%





















n 23 23 23 23 22† 23 23 23 23 23
Average* 11348 4011 1265 0401 0134 0039 0015 0005 0003 0003
SD 3792 1211 0377 0117 0041 0016 0008 0003 0002 0002
CV, % 334 302 298 293 305 404 529 597 616 690
CV, coefficient of variation; MR, molecular response; n, number of participant results submitted; SD, standard deviation.
*Average of participant BCR-ABL1IS results.





















































Fig 1. BCR-ABL1IS results reported for samples A–J for all partici-
pants who performed reverse transcriptase droplet digital polymerase
chain reaction (RTddPCR). Black dots represent individual partici-
pant results. Long horizontal line represents average. Short horizontal
line represents standard deviation.
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BCR-ABLIS)-] compared to a range of 352% for sample E
[MR15 (33% BCR-ABLIS)-] to 594% for sample A [MR40
(001% BCR-ABLIS)-] for RTqPCR for samples between
MR10 (10% BCR-ABLIS)- and MR40 (001% BCR-ABLIS)-.
For deep-response samples, the CV ranged from 468% for
sample I [MR47 (00033% BCR-ABLIS)-] to 706% for sam-
ple J [MR45 (0033% BCR-ABLIS)-] for participants using
RTddPCR compared to a RTqPCR CV range of 714% for
sample H [MR50 (0001% BCR-ABLIS)-] to 1166% for sam-
ple J [MR45 (0033% BCR-ABLIS)-]. A statistically significant
lower CV for RTddPCR (P < 005) could be demonstrated
in seven of the 10 samples (Table SVII). A statistically signif-
icant lower CV for RTddPCR could not be shown in sample
E [MR15 (33% BCR-ABLIS)-], sample A [MR40 (001%
BCR-ABLIS)-] and sample H [MR50 (001% BCR-ABLIS)-].
Nine out of 11 participants RTddPCR results showed bet-
ter linearity from MR10 (10% BCR-ABLIS)- to MR40 (001%
BCR-ABLIS)- (average R2 = 09996) compared to RTqPCR
(average R2 = 09940) (Fig 4; Table SVIII) with six of these
nine being shown to be a statistically significant difference
(Table SVIII). One participant showed the same linearity
with both RTddPCR and RTqPCR, and one participant
showed better linearity with RTqPCR, although this was not
a statistically significant difference. All 11 participants using
RTddPCR had a satisfactory R2 > 099; eight of 11 partici-
pants using RTqPCR had a satisfactory R2 > 099.
Discussion
Measurement of BCR-ABL1 has long since been central to
the management of patients with CML. The European Leu-
kemiaNET (ELN) 2020 recommendations for CML mandate
patients BCR-ABL1 levels are monitored molecularly every
3 months by qPCR, regardless of whether they have achieved





















RTddPCR n 11 11 11 11 11 11 11 11 11 11
Average* 12356 4209 1363 0436 0143 0042 0019 0004 0003 0003
SD 2433 0827 0254 0081 0028 0010 0008 0003 0001 0001
CV, % 197 196 187 185 194 251 441 706 468 493
RTqPCR n 11 11 11 11 11 11 11 11 11 10†
Average* 11733 3955 1331 0393 0123 0035 0013 0006 0003 0002
SD 4659 1390 0501 0155 0051 0021 0008 0007 0002 0001
CV, % 397 352 377 395 413 584 594 1166 754 714
CV, coefficient of variation; MR, molecular response; n, number of participant results submitted; RTddPCR, reverse transcriptase droplet digital
polymerase chain reaction; RTqPCR, reverse transcription quantitative polymerase chain reaction; SD, standard deviation.
*Average of participant BCR-ABL1IS results.












































































































Fig 2. BCR-ABL1IS results reported for samples A–J for participants who performed reverse transcriptase droplet digital polymerase chain reac-
tion (RTddPCR) (A) and reverse transcription quantitative polymerase chain reaction (RTqPCR) (B). Black dots represent individual participant
results. Long horizontal line represents average. Short horizontal line represents standard deviation.
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a MR3.0 while on TKI therapy. The BCR-ABLIS levels at 3, 6,
12 and 18 months are important assessment points and
determine the response to TKI therapy, with key decisions
being made on continuation or switching of treatment. Mea-
surement BCR-ABL1 at deep-response levels is also used in
the management of pregnancy in younger patients,1,19 as well
as for bone marrow transplantation.20 TFR is now an achiev-
able goal for a proportion of patients with CML.
Achievement of a deep MR has been a major criterion for
eligibility for treatment discontinuation studies.5
Despite initial studies showing the potential to deliver
more accurate and precise data on which these important
treatment decisions could be made, RTddPCR has yet to gain
widespread adoption for the measurement of BCR-ABL1;
however, it is showing an increased uptake for the detection
of other haematological variants. There has been a steady
increase in participants using digital PCR in the UK National
External Quality Assessment Services (NEQAS) for Leucocyte
Immunophenotyping (LI) JAK2 p.Val617Phe Mutation Sta-
tus external quality assessment (EQA) programme (Fig-
ure S1) (from 07% of participants in 2015 to 82% in 2020)
and the UK NEQAS LI KIT p.Asp816Val in Mast Cell Dis-
ease EQA programme (from 83% of participants in 2015 to
240% in 2020); however, growth has been minimal in the
BCR-ABL1 (Major) Quantification programme (from 02%
of participants in 2015 to 10% in 2020). A lack of interlabo-
ratory validation studies, the extensive validation required for
a quantitative minimal residual disease test, concerns about
the comparability of results to legacy data, the lack of well-
established best practise guidelines and the need to establish
an IS conversion factor for laboratory developed RTddPCR
tests are likely some of the limiting factors for laboratories
considering adopting RTddPCR for BCR-ABL1 measurement
that have stymied its growth.
The average BCR-ABLIS results submitted by participants
using RTqPCR in the present study was compared to that
from participants using RTddPCR and were seen to be com-
parable, with no statistically significant difference
Fig 3. Linear regression for all participants who performed reverse
transcriptase droplet digital polymerase chain reaction (RTddPCR)
for samples A–G. Coloured lines represent individual participant’s
results. [Colour figure can be viewed at wileyonlinelibrary.com]
(A) (B)
Fig 4. Linear regression for participants who performed both reverse transcriptase droplet digital polymerase chain reaction (RTddPCR) (A) and
reverse transcription quantitative polymerase chain reaction (RTqPCR) (B) for samples A–G. Coloured lines represent individual participant’s
results. [Colour figure can be viewed at wileyonlinelibrary.com]
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demonstrated. This provides confidence to laboratories look-
ing to adopt RTddPCR that the RTddPCR percentage BCR-
ABLIS results can meaningfully compared to legacy percent-
age BCR-ABLIS RTqPCR data in longitudinal analysis.
Nonetheless, comparability of results must still be validated
on a centre-by-centre basis. Both methods achieved sufficient
ABL1 control gene levels (median for participants using
RTqPCR was >80 000 for all samples; median for partici-
pants using RTddPCR was >100 000 for all samples)
(Table SIV; Table SV) to allow laboratories to adhere to cur-
rent best practise requirements for measuring deep MR using
both methods.21
Both RTqPCR and RTddPCR showed good linearity and
sensitivity; however, less interlaboratory variation was
demonstrated in RTddPCR results in all samples down to
MR30, with four of the five samples tested by laboratories
showing a statistically significant difference. Furthermore,
nine out of 11 participants using RTddPCR showed
improved assay linearity compared to RTqPCR down to and
beyond MR30 (01% BCR-ABLIS). This is indicative of the
precision and accuracy inherent to digital PCR due to it
being an end-point, binary enumeration method22 that
reduces the potential for under- or overestimating BCR-
ABL1 levels. RTddPCR had a reduced interlaboratory varia-
tion in all deep-response samples when compared to
RTqPCR, with a statistically significant difference being
demonstrated in two-thirds of the deep-response samples.
No difference in performance was seen in the ability to
detect BCR-ABL1 in ‘deep-response’ samples required by
treatment discontinuation studies; however, stochastic sam-
pling error (Poisson noise) limited the possibility of reliable
detection of BCR-ABL1 when potentially detecting a single
molecule (Cross et al., 201521), given the standard sample
input into the assay. To demonstrate a statistically significant
difference would require an impractical number of replicates
in a study of this scale. The effect of increasing blood draw
volumes and RNA sample input, although potentially chal-
lenging clinically and costly, should be the focus of future
studies.
The present study has demonstrated that RTddPCR using
the QXDX BCR-ABL %IS kit is a viable alternative to the
current ‘gold standard’ RTqPCR. Quantifying samples
directly with no reliance on standard curves, it offers
decreased interlaboratory variation and better assay linearity
when directly compared to RTqPCR. It suggests that
RTddPCR using the QXDX BCR-ABL %IS kit will allow
more comparable management of patients with CML in a
diverse range of clinical scenarios. It also establishes a base-
line performance for RTddPCR using the QXDX BCR-ABL
%IS kit for the measurement of BCR-ABL1 for a diverse
group of laboratories in a range of different countries. This
reproduces the improved accuracy of RTddPCR shown in
single-centre studies,12–15 while additionally demonstrating
the robustness of the approach when applied to a diverse
range of laboratories (research, clinical, translational) in a
wide variety of countries. However, with only 11 laboratories
testing both RTqPCR and RTddPCR, this data will need to
be replicated in a larger dataset using a more diverse range
of digital PCR approaches. The impact RNA extraction and
cDNA synthesis diversity on RTddPCR variability was not
assessed in the present study and should be the focus of
future standardisation projects.
The cost of Bio-Rad’s QXDX BCR-ABL %IS kit is similar
to the automated Cepheid Xpert cartridge-based systems,
but is more expensive than conventional laboratory devel-
oped RTqPCR tests, especially when the extra wells for deep-
response detection are considered.23 This is off set by the
lack of requirement for a standard curve and the reduced
validation required when using a Conformite Europeene
(CE) marked kit given the imminent changes to Europe’s
in vitro diagnostic (IVD) regulations and their impact on
laboratory developed tests.
The ability to detect deep responses with RTddPCR using
the Bio-Rad QXDX BCR-ABL %IS kit, matched with an
improved linearity and reduced interlaboratory CVs, com-
pared to RTqPCR, offers the potential for better classification
of patients according to the ELN 2020 criteria at both major
MR and deep-response level.
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